Tong A W, Lee J C, Stone M J
J Natl Cancer Inst. 1986 Nov;77(5):1023-33.
The immunohistochemical reactivity of biopsy specimens from different human lung tumor cell types was examined with 4 human small cell lung carcinoma (SCLC)-reactive monoclonal antibodies (MoAbs) (SCLC 1096, SCLC 2051, SCLC 3121, and SCLC 5023) generated in this laboratory, with the use of Formalin-fixed, paraffin-embedded tissue sections. Each MoAb reacted preferentially with SCLC tumors (62-97% of 29 cases tested), with low-to-moderate cross-reactivity with non-SCLC tumors (SCLC 1096, 13.7%; SCLC 2051 and SCLC 3121, 9.8% each; SCLC 5023, 41%, of 51 cases tested). None of the 4 MoAbs reacted with nonmalignant lung biopsy specimens. SCLC tumors were characterized by their collective immunoperoxidase reactivity with the MoAb panel of SCLC 2051, SCLC 3121, and SCLC 5023. Based on unequivocal positive reactions with at least 2 of the 3 MoAbs, this MoAb panel correctly identified 97% (28/29) of SCLC cases of 80 lung tumor cases tested. By contrast, only 4 of 51 (7.8%) non-SCLC cases were positive by the same criterion. These observations suggest that immunohistochemical analysis with these SCLC-reactive MoAbs could help in discriminating small cell from other human lung carcinoma cell types.
使用本实验室制备的4种人小细胞肺癌(SCLC)反应性单克隆抗体(MoAbs)(SCLC 1096、SCLC 2051、SCLC 3121和SCLC 5023),对来自不同人类肺肿瘤细胞类型的活检标本进行免疫组织化学反应检测,采用福尔马林固定、石蜡包埋的组织切片。每种MoAb优先与SCLC肿瘤反应(29例检测病例中的62%-97%),与非SCLC肿瘤有低至中度的交叉反应(SCLC 1096为13.7%;SCLC 2051和SCLC 3121各为9.8%;SCLC 5023为41%(51例检测病例))。这4种MoAb均未与非恶性肺活检标本反应。SCLC肿瘤的特征是其与SCLC 2051、SCLC 3121和SCLC 5023的MoAb组合有集体免疫过氧化物酶反应性。基于对3种MoAb中至少2种的明确阳性反应,该MoAb组合正确识别了80例检测的肺肿瘤病例中的97%(28/29)的SCLC病例。相比之下,51例非SCLC病例中只有4例(7.8%)按相同标准呈阳性。这些观察结果表明,用这些SCLC反应性MoAbs进行免疫组织化学分析有助于区分小细胞与其他人类肺癌细胞类型。